News
Treatment with the TROP2 ADC sac-TMT led to a 70% objective response rate and progression-free survival was “significantly improved” as compared to placebo—the second positive readout for the asset this week.
FEATURED STORIES
While the pathogen appears unlikely to trigger a pandemic, analysts see potential for Moderna to build goodwill amid a period of political pressure on vaccine manufacturers.
Clinical trial setbacks have limited the near-term opportunities for some of Daiichi Sankyo’s ADCs but the drug developer is betting near-term readouts will catapult it into the top tier of oncology companies in the coming years.
BioSpace analyzed the pay ratio across 10 major pharmaceutical companies to determine which CEOs were paid the most relative to typical employees. J&J, Eli Lilly and Pfizer once again topped the list.
FROM OUR EDITORS
Read our takes on the biggest stories happening in the industry.
The Department of Health and Human Services is spinning its wheels, unable to establish steady leadership at three major divisions—the CDC and the FDA’s two primary review units.
THE LATEST
Long-term, opportunities may include using the platform as a vehicle for combination therapies from assets developed by multiple companies.
With the turn of the calendar, biopharma and life sciences organizations have bolstered their leadership teams and board with these Movers & Shakers.
Sangamo Therapeutics announced that Sanofi US was returning its rights to SAR445136 as it shifts its approach from personalized cell therapies to allogeneic off-the-shelf genomic approaches.
SomaLogic and Illumina have come together to propel innovation in Proteomics. This partnership represents the rapidly growing high throughput sector of the proteomics market
Working from home can cause burnout and stress. The stress caused leads to low performance sometimes. Here are nine ways to prevent work from home burnout.
Amgen and Generate Biomedicines inked a research partnership to discover and develop protein therapeutics for five clinical targets.
ONK announced an infusion of $21.5 million to propel their NK-powered programs towards IND-enabling studies.
As 2022 gets underway, multiple companies have already announced partnerships that will advance the potential for new medications in various disease indications.
What the appearance of yet another variant shows is the “unpredictability of the emergence of SARS-CoV-2 variants,” according to the researchers who discovered IHU.
Founded in 2014 and number 3 on BioSpace’s NextGen Bio “Class of 2022” life science startups to watch, Eikon Therapeutics today closed on a Series B financing worth $517.8 million.